Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q3 2023 Earnings Presentation
10 slides from Bionano Genomics's earnings presentation, Nov 8, 2023
Slide 1: Q3 2023 Financial Results Webcast & Call
November 2023 Q3 2023 Financial Results Webcast & Call
Slide 2: Legal Disclaimer
© Copyright 2023, Bionano Genomics, Inc. Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan," anticipate,” “estimate,” “intend,” “should,” “believe,” “would,”
Slide 3: Non-GAAP Financial Measures
© Copyright 2023, Bionano Genomics, Inc. Non-GAAP Financial Measures To supplement Bionano’s financial results reported in accordance with U.S. generally accepted accounting principles (GAAP), the Company has provided non-GAAP gross margin and non-GAAP operating expense in this presentation, which a
Slide 4: Corporate Updates
© 2023, Bionano Genomics, Inc. 4 Corporate Updates • Appointed Gülsen Kama as the company’s chief financial officer (CFO), effective September 11, 2023 • Company took significant steps to reduce operating expenses and extend cash runway, in an effort to shorten the path toward profitability
Slide 5: Q3 2023 Business Highlights
© Copyright 2023, Bionano Genomics, Inc. 5 Q3 2023 Business Highlights • Revenues of $9.3M (+29% vs Q3’22) • GAAP gross margin of 30%*; non-GAAP gross margin 32%* • GAAP OpEx $116M; non-GAAP OpEx $31.8M • $33.6M trailing 12-month revenue • FY 23 revenue guidance: $35 – 38M • 6,176 flow cells sold (+
Slide 6: Accelerate Revenue Growth and Operate Efficiently to Achieve Profitability
© Copyright 2023, Bionano Genomics, Inc. Accelerate Revenue Growth and Operate Efficiently to Achieve Profitability 1 2 Expand global adoption and utilization of OGM in hematologic malignancies, cell & gene therapy and rare diseases with a robust end-to-end workflow for efficient detection, analysis
Slide 7: ELEVATE! Anticipated Milestones
© Copyright 2023, Bionano Genomics, Inc. ELEVATE! Anticipated Milestones 1H 2H Planned Product Developments Commercial version of high throughput OGM system in the field Commercial release of VIATM software for OGM heme • Launch high throughput compute solution for OGM, developed in collaboratio
Slide 8: Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense
© Copyright 2023, Bionano Genomics, Inc. 8 Bionano Genomics, Inc. Reconciliation of GAAP Operating Expense to Non-GAAP Operating Expense (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 GAAP gross margin: GAAP revenue $ 9,318,000 $ 7,221,000 $ 25,395,0
Slide 9: Questions & Answers
Questions & Answers 9 Contact: R. Erik Holmlin CEO eholmlin@bionano.com Gülsen Kama CFO gkama@bionano.com
Slide 10: Thank you.
— Thank you.